“International Medical Service in Egypt.”

Apolipoproteins A1 and B In Coronary Heart Disease

Apo-A1 and Apo-B were studied in people suffering from Coronary Heart Disease (CHD) and it was concluded that:

Serum concentrations of Apo-B are increased in cases of CHD; i.e., it is atherogenic because it influences the existence and progression of CHD.

Serum concentrations of Apo-A1 <120 mg/dL are associated with increased risk of CHD. Moreover. Apo-A1 concentrations are low in male survivors with risk of CHD. On the other hand, Apo-A1 serum concentrations >160 mg/dL may be protective. 3. Apo-A1/Apo-B ratio equal to or less than 1.0 occurs in cases of CHD and thus this ratio is an indication of CHD.

Apo-A1 decreased values and Apo-B increased values correlate better with the degree of coronary stenosis than LDL-C and HDL-C values.

The Familial Atherosclerosis Treatment Study (FATS) demonstrated that the treatment with lipid lowering agents on the basis of Apo-B concentration alone in men younger than 62 years of age arid without CHD, is beneficial. Apo-B reduction correlated with the reversal of angiographically evident coronary atherosclerosis thus, reducing the incidence of cardiac events.

Being considerate to provide the best healthcare service, Alfa Laboratory is the only lab. that routinely include the measurement of Apo-A1 and Apo-B in our Lipid Profile: Total cholesterol (TC), HDL-C, LDL-C, triglycerides and the three risk ratios, namely TC/HDL-C. LDL-C/HDL-C, and Apo-A1/Apo-B.

joomla wellnessLorem Ipsum has been the industry's standard dummy text ever since the 1500s...